A targeted drug shrank tumours in more than three-quarters of patients with advanced breast cancer in a phase three trial, while significantly delaying the point at which the disease began to progress. The treatment, trastuzumab…
A targeted drug shrank tumours in more than three-quarters of patients with advanced breast cancer in a phase three trial, while significantly delaying the point at which the disease began to progress. The treatment, trastuzumab…
📌 Learn more: ja.ma/4BoL3NT
📌 Learn more: ja.ma/4BoL3NT
Through a Virtual Mobility Grant from COST Action CA22125 (#PrecisionBTCNetwork), researchers investigated ERBB2 expression, genomic alterations, prognostic value and immune associations to advance precision oncology.
Through a Virtual Mobility Grant from COST Action CA22125 (#PrecisionBTCNetwork), researchers investigated ERBB2 expression, genomic alterations, prognostic value and immune associations to advance precision oncology.
ja.ma/4s9auif
ja.ma/4s9auif
ja.ma/4j8TEO5
ja.ma/4j8TEO5
@mcgillgci.bsky.social
www.nature.com/articles/s42...
@mcgillgci.bsky.social
www.nature.com/articles/s42...
ja.ma/479i4jj
ja.ma/479i4jj
#NPAW2026🇮🇳
#NPAW2026🇮🇳